Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications

References

• World Health Organization. Global Hepatitis Report 2017. Geneva: World Health Organization & Global Hepatitis Programme; 2017 Available from: http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1.
   Google Scholar
• Hutin Y, Desai S, Bulterys M. Preventing hepatitis B virus infection: milestones and targets. Bull World Health Organ. 2018;96(7):443–443A. doi:10.2471/BLT.18.21521029962544
   PubMed Web of Science ®Google Scholar
• Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61(10):1942–1956.2834034
   PubMed Web of Science ®Google Scholar
• World Health Organization. Prevention and Control of Viral Hepatitis Infection: Framework for Global Action. World Health Organization; 2012 Available from: https://www.who.int/hiv/pub/hepatitis/Framework/en/.
   Google Scholar
• World Health Organization. WHO guidelines approved by the guidelines review committee In: Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization; 2015.
   Google Scholar
• Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292(15):771–774. doi:10.1056/NEJM1975041029215031113797
   PubMed Web of Science ®Google Scholar
• Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20(4):992–1000.7795104
   PubMed Web of Science ®Google Scholar
• Komatsu H, Inui A, Sogo T, Tateno A, Shimokawa R, Fujisawa T. Tears from children with chronic hepatitis B virus (HBV) infection are infectious vehicles of HBV transmission: experimental transmission of HBV by tears, using mice with chimeric human livers. J Infect Dis. 2012;206(4):478–485. doi:10.1093/infdis/jis29322508939
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis B and Breastfeeding. World Health Organization; 1996 Available from: http://www.who.int/maternal_child_adolescent/documents/pdfs/hepatitis_b_and_breastfeeding.pdf.
   Google Scholar
• Hepatitis B Questions and Answers for the Public | CDC. (2018, 6 13). Available from: https://www.cdc.gov/hepatitis/hbv/bfaq.htm. Accessed 122, 2018.
   Google Scholar
• Middleman AB, Baker CJ, Kozinetz CA, et al. Duration of protection after infant hepatitis B vaccination series. Pediatrics. 2014;133(6):e1500–e1507. doi:10.1542/peds.2013-211224843060
   PubMed Web of Science ®Google Scholar
• Van Damme P. Long-term protection after hepatitis B vaccine. J Infect Dis. 2016;214(1):1–3. doi:10.1093/infdis/jiv75026802140
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Worldwide implementation of hepatitis B vaccination of newborns, 2006. Wkly Epidemiol Rec. 2008;83(48):429–434.19039844
   PubMedGoogle Scholar
• Wong VC, Ip HM, Reesink HW, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis- B vaccine and hepatitis- B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet. 1984;1(8383):921–926.6143868
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Hepatitis B vaccines. Wkly Epidemiol Rec. 2004;79(28):255–263.15344666
   PubMedGoogle Scholar
• World Health Organisation. Hepatitis B vaccines. Wkly Epidemiol Rec. 2009;84(40):405–419.19817017
   PubMedGoogle Scholar
• World Health Organization. Hepatitis B: fact sheet. ( Reviewed 7 2017). Available from: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 411, 2018.
   Google Scholar
• Wu JN, Li DJ, Zhou Y. Association between timely initiation of hepatitis B vaccine and completion of the hepatitis B vaccine and national immunization program vaccine series. Int J Infect Dis. 2016;51:62–65. doi:10.1016/j.ijid.2016.08.01827592194
   PubMed Web of Science ®Google Scholar
• Yusuf HR, Daniels D, Smith P, Coronado V, Rodewald L. Association between administration of hepatitis B vaccine at birth and completion of the hepatitis B and 4:3:1:3 vaccine series. JAMA. 2000;284(8):978–983.10944643
   PubMed Web of Science ®Google Scholar
• Creati M, Saleh A, Ruff TA, et al. Implementing the birth dose of hepatitis B vaccine in rural Indonesia. Vaccine. 2007;25(32):5985–5993. doi:10.1016/j.vaccine.2007.05.05517604881
   PubMed Web of Science ®Google Scholar
• Cui F, Liang X, Gong X, et al. Preventing hepatitis B though universal vaccination: reduction of inequalities through the GAVI China project. Vaccine. 2013;31(Suppl 9):J29–J35. doi:10.1016/j.vaccine.2012.07.04824331017
   PubMed Web of Science ®Google Scholar
• Murakami H, Van Cuong N, Huynh L, Hipgrave DB. Implementation of and costs associated with providing a birth-dose of hepatitis B vaccine in Viet Nam. Vaccine. 2008;26(11):1411–1419. doi:10.1016/j.vaccine.2008.01.00218262312
   PubMed Web of Science ®Google Scholar
• Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2(8359):1099–1102.6138642
   PubMed Web of Science ®Google Scholar
• Chen SC, Toy M, Yeh JM, Wang JD, Resch S. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment. Pediatrics. 2013;131(4):e1135–e1143. doi:10.1542/peds.2012-126223530168
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization; 2015 Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK305553/
   Google Scholar
• Eke AC, Eleje GU, Eke UA, Xia Y, Liu J. Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus. Cochrane Database Syst Rev. 2017;2:CD008545.28188612
   PubMed Web of Science ®Google Scholar
• Brown RS Jr., McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology (Baltimore, Md). 2016;63(1):319–333. doi:10.1002/hep.28302
   PubMed Web of Science ®Google Scholar
• Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324–2334. doi:10.1056/NEJMoa150866027305192
   PubMed Web of Science ®Google Scholar
• Jourdain G, Ngo-Giang-Huong N, Harrison L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med. 2018;378(10):911–923. doi:10.1056/NEJMoa170813129514030
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.02128427875
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology (Baltimore, Md). 2018;67(4):1560–1599. doi:10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• Zeng H, Cai H, Wang Y, Shen Y. Growth and development of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers. Int J Infect Dis. 2015;33:97–103. doi:10.1016/j.ijid.2014.09.00225449229
   PubMed Web of Science ®Google Scholar
• Zhou C, Yu Y, Yang Q, et al. Motor development delay in offspring is associated with prenatal telbivudine exposure. Medicine (Baltimore). 2018;97(9):e0053. doi:10.1097/MD.000000000001005329489662
   PubMed Web of Science ®Google Scholar
• Ip HM, Lelie PN, Wong VC, Kuhns MC, Reesink HW. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet. 1989;1(8635):406–410.2563788
   PubMed Web of Science ®Google Scholar
• Soderstrom A, Norkrans G, Lindh M. Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand J Infect Dis. 2003;35(11–12):814–819.14723355
   PubMed Web of Science ®Google Scholar
• Ter Borg MJ, Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat. 2008;15(1):37–41. doi:10.1111/j.1365-2893.2007.00894.x18088243
   PubMed Web of Science ®Google Scholar
• Coursaget P, Kane MA. Overview of clinical studies in developing countries In: Ellis RW, editor. Hepatitis B Vaccines in Clinical Practice. New York: Marcel Dekker, Inc; 1993: 209–228.
   Google Scholar
• Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55(6):1215–1221. doi:10.1016/j.jhep.2011.02.03221703206
   PubMed Web of Science ®Google Scholar
• Mahtab MA, Rahman S, Khan M, Karim F. Hepatitis B virus genotypes: an overview. Hepatobiliary Pancreat Dis Int. 2008;7(5):457–464.18842489
   PubMed Web of Science ®Google Scholar
• Hollinger FB. Hepatitis B virus genetic diversity and its impact on diagnostic assays. J Viral Hepat. 2007;14(Suppl 1):11–15. doi:10.1111/j.1365-2893.2007.00910.x
   Web of Science ®Google Scholar
• Carman WF. Molecular variants of hepatitis B virus. Clin Lab Med. 1996;16(2):407–428.8792080
   PubMed Web of Science ®Google Scholar
• Carman WF, Trautwein C, van Deursen FJ, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology (Baltimore, Md). 1996;24(3):489–493. doi:10.1002/hep.510240304
   Web of Science ®Google Scholar
• Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci. 2001;8(3):237–247. doi:10.1159/00005403911385295
   PubMed Web of Science ®Google Scholar
• Francois G, Kew M, Van Damme P, Mphahlele MJ, Meheus A. Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications? Vaccine. 2001;19(28–29):3799–3815.11427251
   PubMed Web of Science ®Google Scholar
• Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res. 2007;127(2):164–176. doi:10.1016/j.virusres.2007.02.02117383765
   PubMed Web of Science ®Google Scholar
• Chiou HL, Lee TS, Kuo J, Mau YC, Ho MS. Altered antigenicity of ‘a‘ determinant variants of hepatitis B virus. J Gen Virol. 1997;78(Pt 10):2639–2645. doi:10.1099/0022-1317-78-10-26399349486
   PubMed Web of Science ®Google Scholar
• Waters JA, Kennedy M, Voet P, et al. Loss of the common “A” determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest. 1992;90(6):2543–2547. doi:10.1172/JCI1161481281839
   PubMed Web of Science ®Google Scholar
• Cariani E, Ravaggi A, Tanzi E, et al. Emergence of hepatitis B virus S gene mutant in a liver transplant recipient. J Med Virol. 1995;47(4):410–415.8636711
   PubMed Web of Science ®Google Scholar
• Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336(8711):325–329.1697396
   PubMed Web of Science ®Google Scholar
• Kajiwara E, Tanaka Y, Ohashi T, et al. Hepatitis B caused by a hepatitis B surface antigen escape mutant. J Gastroenterol. 2008;43(3):243–247. doi:10.1007/s00535-007-2150-918373168
   PubMed Web of Science ®Google Scholar
• Ghaziasadi A, Alavian SM, Norouzi M, Fazeli Z, Jazayeri SM. Mutational analysis of HBs Ag-positive mothers and their infected children despite immunoprophylaxis. Iran J Allergy Asthma Immunol. 2013;12(4):352–360.23996711
   PubMed Web of Science ®Google Scholar
• Seddigh-Tonekaboni S, Lim WL, Young B, et al. Hepatitis B surface antigen variants in vaccinees, blood donors and an interferon-treated patient. J Viral Hepat. 2001;8(2):154–158. doi:10.1046/j.1365-2893.2001.00275.x11264736
   PubMed Web of Science ®Google Scholar
• Yan B, Lv J, Feng Y, et al. Temporal trend of hepatitis B surface mutations in the post-immunization period: 9 years of surveillance (2005-2013) in eastern China. Sci Rep. 2017;7(1):6669. doi:10.1038/s41598-017-07085-z28751727
   PubMed Web of Science ®Google Scholar
• Carman WF, Van Deursen FJ, Mimms LT, et al. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia. Hepatology (Baltimore, Md). 1997;26(6):1658–1666. doi:10.1002/hep.510260640
   Web of Science ®Google Scholar
• Chang MH. Breakthrough HBV infection in vaccinated children in Taiwan: surveillance for HBV mutants. Antivir Ther. 2010;15(3Pt B):463–469. doi:10.3851/IMP155520516566
   PubMed Web of Science ®Google Scholar
• Chong-Jin O, Wei Ning C, Shiuan K, Gek Keow L. Identification of hepatitis B surface antigen variants with alterations outside the “a” determinant in immunized Singapore infants. J Infect Dis. 1999;179(1):259–263. doi:10.1086/3145539841851
   PubMed Web of Science ®Google Scholar
• He C, Nomura F, Itoga S, Isobe K, Nakai T. Prevalence of vaccine-induced escape mutants of hepatitis B virus in the adult population in China: a prospective study in 176 restaurant employees. J Gastroenterol Hepatol. 2001;16(12):1373–1377.11851835
   PubMed Web of Science ®Google Scholar
• Ho M, Mau Y, Lu C, et al. Patterns of circulating hepatitis B surface antigen variants among vaccinated children born to hepatitis B surface antigen carrier and non-carrier mothers. A population-based comparative study. J Biomed Sci. 1998;5(5):355–362. doi:10.1007/BF22534459758909
   PubMed Web of Science ®Google Scholar
• Khamduang W, Gaudy-Graffin C, Ngo-Giang-Huong N, et al. Analysis of residual perinatal transmission of hepatitis B virus (HBV) and of genetic variants in human immunodeficiency virus and HBV co-infected women and their offspring. J Clin Virol. 2013;58(2):415–421. doi:10.1016/j.jcv.2013.06.02523916828
   PubMed Web of Science ®Google Scholar
• Lazarevic I. Clinical implications of hepatitis B virus mutations: recent advances. World J Gastroenterol. 2014;20(24):7653–7664. doi:10.3748/wjg.v20.i24.765324976703
   PubMed Web of Science ®Google Scholar
• Lee KM, Kim YS, Ko YY, et al. Emergence of vaccine-induced escape mutant of hepatitis B virus with multiple surface gene mutations in a Korean child. J Korean Med Sci. 2001;16(3):359–362. doi:10.3346/jkms.2001.16.3.35911410701
   PubMed Web of Science ®Google Scholar
• Oon CJ, Lim GK, Ye Z, et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine. 1995;13(8):699–702.7483783
   PubMed Web of Science ®Google Scholar
• Santantonio T, Gunther S, Sterneck M, et al. Liver graft infection by HBV S-gene mutants in transplant patients receiving long-term HBIg prophylaxis. Hepatogastroenterology. 1999;46(27):1848–1854.10430358
   PubMedGoogle Scholar
• Velu V, Saravanan S, Nandakumar S, et al. Transmission of “a” determinant variants of hepatitis B virus in immunized babies born to HBsAg carrier mothers. Jpn J Infect Dis. 2008;61(1):73–76.18219140
   PubMed Web of Science ®Google Scholar
• von Weizsacker F, Pult I, Geiss K, Wirth S, Blum HE. Selective transmission of variant genomes from mother to infant in neonatal fulminant hepatitis B. Hepatology (Baltimore, Md). 1995;21(1):8–13.
   Web of Science ®Google Scholar
• Kwak MS, Kim YJ. Occult hepatitis B virus infection. World J Hepatol. 2014;6(12):860–869. doi:10.4254/wjh.v6.i12.86025544873
   PubMedGoogle Scholar
• Pan CQ, Yi W, Liu M, Wan G, Hu YH, Zhou MF. Lamivudine therapy during the second vs the third trimester for preventing transmission of chronic hepatitis B. J Viral Hepat. 2017;24(3):246–252. doi:10.1111/jvh.1264028025872
   PubMed Web of Science ®Google Scholar
• Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16(2):94–103. doi:10.1111/j.1365-2893.2008.01056.x19175878
   PubMed Web of Science ®Google Scholar
• Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology (Baltimore, Md). 2014. doi:10.1002/hep.27034
   Web of Science ®Google Scholar
• Han GR, Jiang HX, Yue X, et al. Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2015;22(9):754–762. doi:10.1111/jvh.1237925641421
   PubMed Web of Science ®Google Scholar
• Piratvisuth T, Han GR, Pol S, Dong Y, Trylesinski A. Comprehensive review of telbivudine in pregnant women with chronic hepatitis B. World J Hepatol. 2016;8(9):452–460. doi:10.4254/wjh.v8.i9.45227028961
   PubMed Web of Science ®Google Scholar
• Tan Z, Yin Y, Zhou J, Wu L, Xu C, Hou H. Telbivudine treatment of hepatitis B virus-infected pregnant women at different gestational stages for the prevention of mother-to-child transmission: outcomes of telbivudine treatment during pregnancy. Medicine (Baltimore). 2016;95(40):e4847. doi:10.1097/MD.000000000000486427749537
   PubMed Web of Science ®Google Scholar
• Wu Q, Huang H, Sun X, et al. Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long-term study. Clin Gastroenterol Hepatol. 2015;13(6):1170–1176. doi:10.1016/j.cgh.2014.08.04325251571
   PubMed Web of Science ®Google Scholar
• Chen JZ, Liao ZW, Huang FL, et al. Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load. Sci Rep. 2017;7(1):4132. doi:10.1038/s41598-017-04479-x28646142
   PubMed Web of Science ®Google Scholar
• Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36(6):687–696. doi:10.1086/36808312627352
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125(6):1714–1722.14724824
   PubMed Web of Science ®Google Scholar
• Pallier C, Castera L, Soulier A, et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol. 2006;80(2):643–653. doi:10.1128/JVI.80.2.643-653.200616378967
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136(2):486–495. doi:10.1053/j.gastro.2008.10.02619027013
   PubMed Web of Science ®Google Scholar
• Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (Baltimore, Md). 2010;51(2):422–430. doi:10.1002/hep.23327
   PubMed Web of Science ®Google Scholar
• Liu Y, Corsa AC, Buti M, et al. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat. 2017;24(1):68–74. doi:10.1111/jvh.1261327658343
   PubMed Web of Science ®Google Scholar
• Boyd A, Gozlan J, Maylin S, et al. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications. Hepatology (Baltimore, Md). 2014;60(2):497–507. doi:10.1002/hep.27182
   Web of Science ®Google Scholar
• Price H, Dunn D, Pillay D, et al. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS One. 2013;8(7):e68152. doi:10.1371/journal.pone.006815223874527
   PubMed Web of Science ®Google Scholar
• Bihl F, Martinetti G, Wandeler G, et al. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. BMC Gastroenterol. 2015;15:79. doi:10.1186/s12876-015-0308-026152237
   PubMed Web of Science ®Google Scholar
• Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12(4):341–353. doi:10.1016/S1473-3099(11)70314-022326017
   PubMed Web of Science ®Google Scholar
• Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137(5):1593-1608e1591-1592. doi:10.1053/j.gastro.2009.08.063
   Web of Science ®Google Scholar
• Qi X, Xiong S, Yang H, Miller M, Delaney W. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007;12(3):355–362.17591025
   PubMed Web of Science ®Google Scholar
• Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005;10(6):727–734.16218172
   PubMed Web of Science ®Google Scholar
• Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology (Baltimore, Md). 2009;49(4):1158–1165. doi:10.1002/hep.22790
   Web of Science ®Google Scholar
• Lacombe K, Boyd A, Lavocat F, et al. High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. Hepatology (Baltimore, Md). 2013;58(3):912–922. doi:10.1002/hep.26374
   Web of Science ®Google Scholar
• Rodriguez-Frias F, Jardi R, Schaper M, et al. Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response. Antivir Ther. 2008;13(8):991–999.19195324
   PubMed Web of Science ®Google Scholar
• Delaney W, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50(7):2471–2477. doi:10.1128/AAC.00138-0616801428
   PubMed Web of Science ®Google Scholar
• Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol. 2006;78(Suppl 1):S52–55. doi:10.1002/jmv.2060816622878
   PubMed Web of Science ®Google Scholar
• Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother. 2008;61(4):766–768. doi:10.1093/jac/dkn01418218641
   PubMed Web of Science ®Google Scholar
• Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology. 2002;293(2):305–313. doi:10.1006/viro.2001.124611886250
   PubMed Web of Science ®Google Scholar
• Cooley L, Ayres A, Bartholomeusz A, et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. Aids. 2003;17(11):1649–1657. doi:10.1097/01.aids.0000060414.18106.5312853747
   PubMed Web of Science ®Google Scholar
• Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol. 2002;25(2):97–106.12367644
   PubMed Web of Science ®Google Scholar
• Clements CJ, Coghlan B, Creati M, Locarnini S, Tedder RS, Torresi J. Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization? Bull World Health Organ. 2010;88(1):66–73. doi:10.2471/BLT.08.06572220428355
   PubMed Web of Science ®Google Scholar
• Kamili S, Sozzi V, Thompson G, et al. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology (Baltimore, Md). 2009;49(5):1483–1491. doi:10.1002/hep.22796
   Web of Science ®Google Scholar
• Lee SY, Choi MS, Lee D, et al. Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy. J Korean Med Sci. 2005;20(3):433–437. doi:10.3346/jkms.2005.20.3.43315953865
   PubMed Web of Science ®Google Scholar
• Ayres A, Yuen L, Jackson KM, et al. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations. J Viral Hepat. 2014;21(11):809–817. doi:10.1111/jvh.1221224329944
   PubMed Web of Science ®Google Scholar